Dr. Jeffrey L. Cummings

Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, Neurodegenerative diseases, Alzheimer’s disease, Drug development, Clinical trials, Neurotherapeutics

Biography

UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.

Dr. Cummings leads the UNLV Clinical Trials Observatory, the world’s only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease. 

Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer’s Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.

Named a “Rock Star of Science” by Gentleman’s Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer’s disease, and clinical trials.

His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry’s Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award, and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

P.B.S.
A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!
The New York Times
Over the past few years, scientists have learned that Ozempic and related drugs developed to treat Type 2 diabetes can improve the health of the liver, kidney and heart. Is it such a stretch to think they could also treat neurological disorders? Perhaps — at least when it comes to Alzheimer’s disease.
MedPage Today
Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.
Medscape
Detailed results from the phase 3 EVOKE and EVOKE+ trials of the oral GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) in early Alzheimer’s disease (AD) have been presented. The initial negative topline results announced last week by the company were met with disappointment in the AD research community, but the newly presented biomarker data offer some grounds for optimism and may point to a potential path forward.

Articles Featuring Dr. Jeffrey L. Cummings

From left to right: Aditi Singh, MD; Kate Martin, MD; Kavita Batra, PhD; and Deborah Kuhls, MD
Research | September 2, 2025

The medical school is dedicated to expanding its research curriculum, shaping the future of graduate medical education (GME).